Need help finding what you are looking for?
Contact Us
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1882970
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1882970
Pediatric Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
PUBLISHED:
PAGES: 159 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Growth Factors of pediatric vaccines Market
The global pediatric vaccines market is experiencing strong growth driven by rising childhood immunization programs, expanding government support, and increasing focus on vaccine-preventable diseases. According to the report, the pediatric vaccines market size stood at USD 45.36 billion in 2024, and is projected to increase to USD 46.86 billion in 2025, before reaching USD 95.04 billion by 2032, reflecting a robust CAGR of 10.6% from 2025 to 2032. In 2024, North America dominated the market with a 43.23% share, owing to strong healthcare systems, high immunization coverage, and frequent product launches.
Pediatric vaccines play a crucial role in strengthening immunity among children and preventing life-threatening diseases such as polio, measles, malaria, pneumococcal infections, mumps, and more. The market is supported by major companies- including GSK plc., Merck & Co., Inc., and Sanofi-that are expanding production capacity to meet rising global demand. Increasing government and nonprofit investments aimed at protecting children from vaccine-preventable diseases further fuel market expansion. For instance, in June 2025, the Gates Foundation invested USD 1.60 billion over five years to support Gavi's vaccination programs worldwide.
Market Dynamics
Drivers
Growing government support and large-scale childhood vaccination programs are major drivers of the market. International organizations such as UNICEF and GAVI collaborate with governments to procure vaccines and deliver immunization services. As an example, GAVI reported in January 2025 that since 2023, UNICEF has delivered over 9.8 million malaria vaccine doses to children across 17 African nations. This highlights the increasing scale of pediatric immunization initiatives globally.
Restraints
Despite strong worldwide demand, vaccine hesitancy continues to hinder adoption in many low- and middle-income countries. Misinformation, mistrust in healthcare systems, cultural barriers, and limited access to medical facilities contribute to low vaccination rates. WHO identified vaccine hesitancy as one of the top ten global health threats in 2019, and levels of mistrust have increased since the COVID-19 pandemic.
Opportunities
Significant opportunities exist through growing research and development initiatives targeting diseases that currently lack approved vaccines. Highly contagious diseases such as Lassa fever and Enterotoxigenic E. coli (ETEC) continue to affect thousands of children. As per a February 2024 NIH report, Lassa fever causes 5,000 deaths annually and accounts for 100,000-300,000 cases each year, with no approved vaccine available yet. This unmet need is encouraging global expansion of vaccine research pipelines.
Challenges
A major challenge for the pediatric vaccines market is the lack of cold chain storage and logistics infrastructure in low-income regions. According to a 2021 report by Sustainable Energy for All, 2.7 billion people lack dependable access to vaccines due to supply chain limitations and unreliable cold storage-leading to vaccine wastage and reduced accessibility.
Market Trends
One of the most significant trends is the increasing global shift toward combination vaccines, which reduce the number of injections children require, simplify immunization schedules, and improve overall vaccination coverage. For example, in July 2025, GAVI introduced a hexavalent vaccine in Mauritania and Senegal that protects against six diseases, replacing previous pentavalent and IPV vaccines.
Segmentation Highlights
The recombinant/conjugate/subunit vaccine type dominated the market in 2024 due to high effectiveness and regulatory support. Live attenuated, inactivated, mRNA, viral vector, and toxoid vaccines are also witnessing strong demand driven by robust research pipelines and expanding approvals.
By disease indication, viral disease vaccines held the largest share owing to the high prevalence of measles, rubella, polio, HPV, and influenza. Bacterial disease vaccines are set to grow steadily, supported by new launches like Abbott's PneumoShield 14 in 2024.
The oral route leads the market due to ease of administration and suitability for mass immunization programs, while parenteral vaccines continue to expand with advanced delivery technologies.
Regional Outlook
North America generated USD 19.61 billion in revenue in 2024, solidifying its leadership through strong infrastructure and innovation. Europe maintains high immunization rates but faces supply gaps, while Asia Pacific is expected to grow fastest due to rising disease outbreaks and vaccination demand. Latin America and the Middle East & Africa continue to expand through WHO and GAVI-supported programs.
Conclusion
With the market expected to rise from USD 45.36 billion in 2024 to USD 95.04 billion by 2032, the pediatric vaccines industry remains on a strong growth trajectory. Government funding, technological advancements, and expanding immunization programs will continue to drive global market momentum through 2032.
Segmentation By Type
- Live Attenuated
- Inactivated
- Recombinant/Conjugate/Subunit
- mRNA Vaccine
- Viral Vectors Vaccines
- Toxoid
- Others
By Disease Indication
- Viral Diseases
- Hepatitis
- Hepatitis A
- Hepatitis B
- Polio
- RSV
- Influenza
- HPV
- Measles/Mumps/Rubella
- Rotavirus
- Shingles (Herpes Zoster)
- Others
- Bacterial Diseases
- Pneumococcal Diseases
- DTP
- Meningococcal Diseases
- Others
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Region
- North America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
- Germany
- U.K
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Asia Pacific (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Product Code: FBI113756
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Regulatory Scenarios, By Key Countries/Regions
- 4.2. Vaccination Coverage- By Key Countries/ Regions
- 4.3. Government Immunization Programs for Children- By Key Countries/ Regions
- 4.4. Technological Advancements in Pediatric Vaccines Market
- 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
5. Global Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Live Attenuated
- 5.1.2. Inactivated
- 5.1.3. Recombinant/Conjugate/Subunit
- 5.1.4. mRNA Vaccine
- 5.1.5. Viral Vectors Vaccines
- 5.1.6. Toxoid
- 5.1.7. Others
- 5.2. Market Analysis, Insights and Forecast - By Disease Indication
- 5.2.1. Viral Diseases
- 5.2.1.1. Hepatitis A
- 5.2.1.2. Hepatitis B
- 5.2.1.3. Polio
- 5.2.1.4. RSV
- 5.2.1.5. Influenza
- 5.2.1.6. HPV
- 5.2.1.7. MMR
- 5.2.1.8. Rotavirus
- 5.2.1.9. Shingles
- 5.2.1.10. Others
- 5.2.2. Bacterial Diseases
- 5.2.2.1. Pneumococcal Diseases
- 5.2.2.2. DTP
- 5.2.2.3. Meningococcal Diseases
- 5.2.2.4. Others
- 5.2.1. Viral Diseases
- 5.3. Market Analysis, Insights and Forecast - By Route of Administration
- 5.3.1. Oral
- 5.3.2. Parenteral
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital & Retail Pharmacies
- 5.4.2. Government Suppliers
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Live Attenuated
- 6.1.2. Inactivated
- 6.1.3. Recombinant/Conjugate/Subunit
- 6.1.4. mRNA Vaccine
- 6.1.5. Viral Vectors Vaccines
- 6.1.6. Toxoid
- 6.1.7. Others
- 6.2. Market Analysis, Insights and Forecast - By Disease Indication
- 6.2.1. Viral Diseases
- 6.2.1.1. Hepatitis A
- 6.2.1.2. Hepatitis B
- 6.2.1.3. Polio
- 6.2.1.4. RSV
- 6.2.1.5. Influenza
- 6.2.1.6. HPV
- 6.2.1.7. MMR
- 6.2.1.8. Rotavirus
- 6.2.1.9. Shingles
- 6.2.1.10. Others
- 6.2.2. Bacterial Diseases
- 6.2.2.1. Pneumococcal Diseases
- 6.2.2.2. DTP
- 6.2.2.3. Meningococcal Diseases
- 6.2.2.4. Others
- 6.2.1. Viral Diseases
- 6.3. Market Analysis, Insights and Forecast - By Route of Administration
- 6.3.1. Oral
- 6.3.2. Parenteral
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital & Retail Pharmacies
- 6.4.2. Government Suppliers
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Live Attenuated
- 7.1.2. Inactivated
- 7.1.3. Recombinant/Conjugate/Subunit
- 7.1.4. mRNA Vaccine
- 7.1.5. Viral Vectors Vaccines
- 7.1.6. Toxoid
- 7.1.7. Others
- 7.2. Market Analysis, Insights and Forecast - By Disease Indication
- 7.2.1. Viral Diseases
- 7.2.1.1. Hepatitis A
- 7.2.1.2. Hepatitis B
- 7.2.1.3. Polio
- 7.2.1.4. RSV
- 7.2.1.5. Influenza
- 7.2.1.6. HPV
- 7.2.1.7. MMR
- 7.2.1.8. Rotavirus
- 7.2.1.9. Shingles
- 7.2.1.10. Others
- 7.2.2. Bacterial Diseases
- 7.2.2.1. Pneumococcal Diseases
- 7.2.2.2. DTP
- 7.2.2.3. Meningococcal Diseases
- 7.2.2.4. Others
- 7.2.1. Viral Diseases
- 7.3. Market Analysis, Insights and Forecast - By Route of Administration
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital & Retail Pharmacies
- 7.4.2. Government Suppliers
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.5.1. Germany
- 7.5.2. U.K.
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Live Attenuated
- 8.1.2. Inactivated
- 8.1.3. Recombinant/Conjugate/Subunit
- 8.1.4. mRNA Vaccine
- 8.1.5. Viral Vectors Vaccines
- 8.1.6. Toxoid
- 8.1.7. Others
- 8.2. Market Analysis, Insights and Forecast - By Disease Indication
- 8.2.1. Viral Diseases
- 8.2.1.1. Hepatitis A
- 8.2.1.2. Hepatitis B
- 8.2.1.3. Polio
- 8.2.1.4. RSV
- 8.2.1.5. Influenza
- 8.2.1.6. HPV
- 8.2.1.7. MMR
- 8.2.1.8. Rotavirus
- 8.2.1.9. Shingles
- 8.2.1.10. Others
- 8.2.2. Bacterial Diseases
- 8.2.2.1. Pneumococcal Diseases
- 8.2.2.2. DTP
- 8.2.2.3. Meningococcal Diseases
- 8.2.2.4. Others
- 8.2.1. Viral Diseases
- 8.3. Market Analysis, Insights and Forecast - By Route of Administration
- 8.3.1. Oral
- 8.3.2. Parenteral
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital & Retail Pharmacies
- 8.4.2. Government Suppliers
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Live Attenuated
- 9.1.2. Inactivated
- 9.1.3. Recombinant/Conjugate/Subunit
- 9.1.4. mRNA Vaccine
- 9.1.5. Viral Vectors Vaccines
- 9.1.6. Toxoid
- 9.1.7. Others
- 9.2. Market Analysis, Insights and Forecast - By Disease Indication
- 9.2.1. Viral Diseases
- 9.2.1.1. Hepatitis A
- 9.2.1.2. Hepatitis B
- 9.2.1.3. Polio
- 9.2.1.4. RSV
- 9.2.1.5. Influenza
- 9.2.1.6. HPV
- 9.2.1.7. MMR
- 9.2.1.8. Rotavirus
- 9.2.1.9. Shingles
- 9.2.1.10. Others
- 9.2.2. Bacterial Diseases
- 9.2.2.1. Pneumococcal Diseases
- 9.2.2.2. DTP
- 9.2.2.3. Meningococcal Diseases
- 9.2.2.4. Others
- 9.2.1. Viral Diseases
- 9.3. Market Analysis, Insights and Forecast - By Route of Administration
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital & Retail Pharmacies
- 9.4.2. Government Suppliers
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Live Attenuated
- 10.1.2. Inactivated
- 10.1.3. Recombinant/Conjugate/Subunit
- 10.1.4. mRNA Vaccine
- 10.1.5. Viral Vectors Vaccines
- 10.1.6. Toxoid
- 10.1.7. Others
- 10.2. Market Analysis, Insights and Forecast - By Disease Indication
- 10.2.1. Viral Diseases
- 10.2.1.1. Hepatitis A
- 10.2.1.2. Hepatitis B
- 10.2.1.3. Polio
- 10.2.1.4. RSV
- 10.2.1.5. Influenza
- 10.2.1.6. HPV
- 10.2.1.7. MMR
- 10.2.1.8. Rotavirus
- 10.2.1.9. Shingles
- 10.2.1.10. Others
- 10.2.2. Bacterial Diseases
- 10.2.2.1. Pneumococcal Diseases
- 10.2.2.2. DTP
- 10.2.2.3. Meningococcal Diseases
- 10.2.2.4. Others
- 10.2.1. Viral Diseases
- 10.3. Market Analysis, Insights and Forecast - By Route of Administration
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital & Retail Pharmacies
- 10.4.2. Government Suppliers
- 10.4.3. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2024)
- 11.2. Company Profiles
- 11.2.1. Merck & Co., Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products & services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Sanofi.
- 11.2.2.1. Overview
- 11.2.2.2. Products & services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Bharat Biotech.
- 11.2.3.1. Overview
- 11.2.3.2. Products & services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. GSK plc.
- 11.2.4.1. Overview
- 11.2.4.2. Products & services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. SINOVAC
- 11.2.5.1. Overview
- 11.2.5.2. Products & services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Serum Institute of India Pvt. Ltd.
- 11.2.6.1. Overview
- 11.2.6.2. Products & services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.
- 11.2.7.1. Overview
- 11.2.7.2. Products & services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Panacea Biotec
- 11.2.8.1. Overview
- 11.2.8.2. Products & services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Bio Farma
- 11.2.9.1. Overview
- 11.2.9.2. Products & services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. AJ Vaccines A/S
- 11.2.10.1. Overview
- 11.2.10.2. Products & services
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.11. Beijing Institute of Biological Products Co., Ltd.
- 11.2.11.1. Overview
- 11.2.11.2. Products & services
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Strategies
- 11.2.11.6. Financials (Based on Availability)
- 11.2.1. Merck & Co., Inc.
Product Code: FBI113756
List of Tables
- Table 1: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
- Table 2: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
- Table 3: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
- Table 4: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
- Table 5: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
- Table 6: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
- Table 7: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Region, 2019-2032
- Table 8: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
- Table 9: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
- Table 10: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
- Table 11: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
- Table 12: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
- Table 13: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
- Table 14: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
- Table 15: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
- Table 16: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
- Table 17: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
- Table 18: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
- Table 19: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
- Table 20: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
- Table 21: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 22: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
- Table 23: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
- Table 24: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
- Table 25: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
- Table 26: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
- Table 27: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
- Table 28: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 29: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
- Table 30: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
- Table 31: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
- Table 32: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
- Table 33: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
- Table 34: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
- Table 35: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 36: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
- Table 37: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
- Table 38: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
- Table 39: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
- Table 40: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
- Table 41: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
- Table 42: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
List of Figures
- Figure 1: Global Pediatric Vaccines Market Revenue Breakdown (USD billion, %), By Region, 2024 & 2032
- Figure 2: Global Pediatric Vaccines Market Value Share (%), By Type, 2024 & 2032
- Figure 3: Global Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024 & 2032
- Figure 4: Global Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024 & 2032
- Figure 5: Global Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024 & 2032
- Figure 6: Global Pediatric Vaccines Market Value Share (%), By Region, 2024 & 2032
- Figure 7: North America Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
- Figure 8: North America Pediatric Vaccines Market Value Share (%), By Type, 2024
- Figure 9: North America Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
- Figure 10: North America Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
- Figure 11: North America Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
- Figure 12: North America Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
- Figure 13: North America Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
- Figure 14: North America Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
- Figure 15: North America Pediatric Vaccines Market Value (USD billion), By Country, 2024 & 2032
- Figure 16: North America Pediatric Vaccines Market Value Share (%), By Country, 2024
- Figure 17: Europe Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
- Figure 18: Europe Pediatric Vaccines Market Value Share (%), By Type, 2024
- Figure 19: Europe Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
- Figure 20: Europe Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
- Figure 21: Europe Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
- Figure 22: Europe Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
- Figure 23: Europe Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
- Figure 24: Europe Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
- Figure 25: Europe Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 26: Europe Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2024
- Figure 27: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
- Figure 28: Asia Pacific Pediatric Vaccines Market Value Share (%), By Type, 2024
- Figure 29: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
- Figure 30: Asia Pacific Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
- Figure 31: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
- Figure 32: Asia Pacific Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
- Figure 33: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
- Figure 34: Asia Pacific Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
- Figure 35: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 36: Asia Pacific Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2024
- Figure 37: Latin America Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
- Figure 38: Latin America Pediatric Vaccines Market Value Share (%), By Type, 2024
- Figure 39: Latin America Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
- Figure 40: Latin America Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
- Figure 41: Latin America Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
- Figure 42: Latin America Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
- Figure 43: Latin America Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
- Figure 44: Latin America Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
- Figure 45: Latin America Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 46: Latin America Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2024
- Figure 47: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
- Figure 48: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Type, 2024
- Figure 49: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
- Figure 50: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
- Figure 51: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
- Figure 52: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
- Figure 53: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
- Figure 54: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
- Figure 55: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 56: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2024
- Figure 57: Global Pediatric Vaccines Market Share (%), By Company, 2024
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.